43 year old Caucasian male
Switched to ALTUVIIIO November 2023
Otis has moderate hemophilia A with FVIII levels at 4% and works a physically demanding job as a truck loader. Otis was treating his bleeds on-demand with SHL therapy. Otis presented to the clinic with right knee pain, swelling, and limited range of motion. He also complained of back pain, and has a history of pain in the right shoulder and left ankle.
Patient Information
- Experienced recurrent joint bleeding 2 to 3x a month, affecting his ability to work
- Target joints include knees and right shoulder. Otis also has a history of left-ankle bleeds
- Overweight (lives a sedentary lifestyle outside of work, as he was told in the past that he was unable to exercise as a patient with hemophilia)
- Sleep apnea
- Family with known hemophilia A
- BP: 117/80
- BMI: 36.21
- Right knee has a limited ROM compared to left (R KN +6-125, L KN 0-125)
- Baseline FVIII levels at 4% (date obtained: April 2023)
Otis’ Path to High Sustained Factor Replacement Therapy, ALTUVIIIO
Diagnosis
- Birth: Moderate hemophilia A (Factor VIII: 4%)
After diagnosis
Otis has been managing his pain due to breakthrough bleeds with analgesics, and has been noncompliant with the on-demand standard half-life therapy dosing instruction for treating his bleeds.
- Otis initially worked a sedentary job and experienced minimal bleeds
- After changing jobs, bleed occurrence increased to 2 to 3x a month requiring him to take time off work
- Recently experienced bleed with severe pain, requiring bracing and absence from work
Before ALTUVIIIO
- Persistent, frequent bleeds and pain following a job switch
Considering the switch
Provider and Otis discussed:
- Frequent bleeds and lifestyle impact, such as recovery time and ability to work
- Worries of increased treatment burden with prophylaxis vs current on-demand treatment
Provider and Otis determined ALTUVIIIO was the best fit for him to1,2:
- Establish early bleed prevention
- Improve bleed protection
- Reduce pain caused by bleeds
- Alleviate concerns about prophylaxis treatment burden with once-weekly dosing
After ALTUVIIIO
Switched to ALTUVIIIO: November 2023
- Since starting ALTUVIIIO prophylaxis, Otis has remained compliant with his once-weekly dosing and has reported 0 episodes of breakthrough bleeding
Do you have patients like Otis?
If so, it may be worth it to consider the following:
How good is good enough?
Do you have patients who feel that they are doing okay on their current treatment?
Choosing the right treatment
How would you discuss switching to a more appropriate treatment option, like ALTUVIIIO, with patients like Otis?
Unlocking high sustained factor levels
Do you think high sustained factor levels and once-weekly dosing with ALTUVIIIO could benefit your patients like Otis?
BMI=body mass index; BP=blood pressure; FVIII=Factor VIII; L KN=left knee; R KN=right knee; ROM=range of motion; SHL=standard half-life.
Other ALTUVIIIO patients that made the switch!
Meet Peter
A 32 year old reverend with severe hemophilia A previously on prophylaxis therapy.
Meet Noah
A 2 year old who was diagnosed with severe hemophilia A at birth due to a de novo mutation and was treating with prophylaxis therapy.
Learn how ALTUVIIIO was studied
The XTEND-1 trial studied ALTUVIIIO in the prophylaxis, on-demand, and perioperative settings in adult and adolescent patients.
What’s next?
If you’re interested in learning more about ALTUVIIIO, why not set up a chat with one of our representatives?
Indication
References: 1. ALTUVIIIO Prescribing Information. Bioverativ Therapeutics Inc. Waltham, MA. 2. von Drygalski A, et al. N Engl J Med. 2023;388(4):310-318.
